Stage IV Melanoma: Clinical Trials

36 trials for Stage IV Melanoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 9 terminated, 3 unknown, 2 withdrawn. 36 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 136Completed 21, Terminated 9, Unknown 3, Withdrawn 2, Active not recruiting 1
Phase 212Completed 7, Terminated 4, Unknown 1

Follow Stage IV Melanoma: new trials by email Literature Review of Stage IV Melanoma trials Research Report on Stage IV Melanoma

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Cyclophosphamide, Fludarabine, Lifileucel - Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Phase 1Active not recruitingRichard Wu22022-07-012026-02-24
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
ImmunicomAIAC - Stage IV Non-small Cell Lung Cancer, Stage IV Melanoma
Phase 1UnknownDr. Ronnie Shapira302020-02-242021-03-24
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
TBX-3400 - Stage III Melanoma, Stage IV Melanoma
Phase 1UnknownTaiga Biotechnologies, Inc.722019-06-022022-05-03
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedUniversity of Colorado, Denver262017-10-312024-10-01
Radiation Use During Vemurafenib Treatment
Radiation therapy, Vemurafenib - BRAFV600 Mutation, Stage IV Melanoma
Phase 1WithdrawnUniversity of Utah2017-06-012017-05-24
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation - Stage IV Melanoma
Phase 1 / Phase 2UnknownVirogen Biotechnology Inc.632017-01-012016-12-13
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
IMP321 (eftilagimod alpha), Pembrolizumab - Stage IV Melanoma, Stage III Melanoma
Phase 1CompletedImmutep Australia Pty. Ltd.242016-04-012019-12-18
Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma
lymph node, X-ACT - Stage IIIC Skin Melanoma, Stage IV Melanoma
Phase 1TerminatedCase Comprehensive Cancer Center32015-03-172018-12-06
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer
Phase 1CompletedWake Forest University Health Sciences172014-12-012018-07-03
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedNewLink Genetics Corporation1312014-07-012026-05-29
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma
Phase 1TerminatedNational Cancer Institute (NCI)52013-05-012014-09-25
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS) - Recurrent Melanoma, Stage IV Melanoma
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University172012-11-092025-05-16
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma
Phase 1CompletedFred Hutchinson Cancer Center122012-03-012014-04-21
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide - Stage IV Melanoma
Phase 1TerminatedFred Hutchinson Cancer Center122010-04-012011-12-21
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Lenvatinib, Dacarbazine - Stage IV Melanoma
Phase 1 / Phase 2CompletedEisai Inc.972010-04-012016-10-10
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma
Phase 1CompletedAbramson Cancer Center at Penn Medicine252010-02-012020-04-07
Dinaciclib in Treating Patients With Stage III-IV Melanoma
dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)122009-09-012017-04-04
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
cediranib maleate, whole-brain radiation therapy - Male Breast Cancer, Stage IV Breast Cancer
Phase 1TerminatedNational Cancer Institute (NCI)182009-08-012013-03-08
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center32009-07-012022-11-15
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
ipilimumab, cyclophosphamide, biopsy - Recurrent Melanoma, Stage IV Melanoma
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center102009-02-012017-04-19

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Melanoma (36)  ·  Carcinoma, Renal Cell (7)  ·  Brain Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Breast Neoplasms (3)  ·  Breast Neoplasms, Male (3)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Colonic Neoplasms (2)  ·  Astrocytoma (1)  ·  Carcinoma, Islet Cell (1)  ·  Carcinoma, Medullary (1)  ·  Carcinoma, Merkel Cell (1)  ·  Congenital Abnormalities (1)  ·  Ependymoma (1)  ·  Esthesioneuroblastoma, Olfactory (1)

Broader conditions

Neoplasms by Histologic Type (36)  ·  Neoplasms by Site (36)  ·  Neoplasms, Germ Cell and Embryonal (36)  ·  Neoplasms, Nerve Tissue (36)  ·  Neuroectodermal Tumors (36)  ·  Neuroendocrine Tumors (36)  ·  Nevi and Melanomas (36)  ·  Skin Diseases (36)  ·  Skin and Connective Tissue Diseases (36)  ·  Neoplasms (35)  ·  Skin Neoplasms (35)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)  ·  Neoplasms, Glandular and Epithelial (9)  ·  Urogenital Diseases (9)

Interventions

Cyclophosphamide (7)  ·  Interleukin-2 (6)  ·  aldesleukin (6)  ·  Biopsy (5)  ·  Immunohistochemistry (5)  ·  Polymerase Chain Reaction (5)  ·  pembrolizumab (5)  ·  Ipilimumab (4)  ·  Vemurafenib (3)  ·  CTLA-4 Antigen (2)  ·  Dacarbazine (2)  ·  Immunologic Techniques (2)  ·  Introns (2)  ·  Nivolumab (2)  ·  Radiosurgery (2)

Sponsors

National Cancer Institute (NCI) (10)  ·  Fred Hutchinson Cancer Center (5)  ·  Case Comprehensive Cancer Center (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Dr. Ronnie Shapira (1)  ·  Eisai Inc. (1)  ·  Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1)  ·  Immutep Australia Pty. Ltd. (1)  ·  John P. Fruehauf (1)  ·  Kyowa Kirin, Inc. (1)  ·  Mayo Clinic (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  NewLink Genetics Corporation (1)  ·  Richard Wu (1)

Countries

United States (32)  ·  Australia (2)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Cassian Yee (3)  ·  Frank Hodi (2)  ·  Sylvia Lee (2)  ·  Wenyin Shi, MD, PhD (2)  ·  Andres Forero, MD (1)  ·  April Eichler (1)  ·  Aude Chapuis (1)  ·  Dave Harish (1)  ·  David Solit (1)  ·  Ernest C. Borden, MD (1)  ·  Gary Hudes (1)  ·  Jason Chesney, MD, PhD (1)  ·  Jason Luke (1)  ·  Jeffrey Weber (1)  ·  John Fruehauf, MD (1)

Results publications

PMID 25795722, PMID 27269940, PMID 28816150

NIH funding

K12CA076930 (3), U01CA062490 (3), P30CA006516 (2), N01CM62202 (1), P30CA012197 (1), P30CA016672 (1), P30CA043703 (1), R21CA105776 (1), R21CA128283 (1), R21CA137647 (1), U01CA062505 (1), U01CA069856 (1), UM1CA186709 (1)